DIGNITANA REVISES 2017 PROJECTIONS FOLLOWING PRODUCTION DELAYS
Lund, Sweden—September 29, 2017—Dignitana AB, a world leader in medical scalp cooling technology and manufacturer of the DigniCap® Scalp Cooling System, today announces a decrease in 2017 sales projections citing production delays.
The relocation of a major manufacturer of the DigniCap® system resulted in a production halt for two months. This in turn has led to a reduction of product availability, and thus, Dignitana has not been able to deliver orders at a planned amount. The move has now been completed and production has returned to normal capacity.
The production halt will affect sales in Q3 and Q4 with approximately SEK 4 million. Dignitana will make efforts to deliver systems at a higher rate during Q4 and in Q1 of 2018, thus being able to recover parts of the temporarily lost sales.
Caren Browning Semmy Rülf
King + Company Chairman of the board, Dignitana AB
00 1 212 561-7464 +46 (0)709-312730
About Dignitana AB (publ)
Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. For more information visit www.dignitana.se
About The DigniCap® Scalp Cooling System
DigniCap® is a patented scalp cooling system that offers cancer patients the ability to keep their hair during chemotherapy. DigniCap® provides continuous cooling with high efficacy, safety and acceptable patient comfort. www.dignicap.com
This information is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 14:30 (CET), 29 September 2017.